NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
stocks
ASX data center player sells US assets to bolster balance sheet
Asset sale in response to growing investor concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.20 | 32.10 | 0.35% |
| CAC 40 | 8,299.42 | 237.11 | 2.94% |
| DAX 40 | 24,918.69 | 516.99 | 2.12% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,438.66 | 219.55 | 2.15% |
| HKSE | 26,575.10 | 361.32 | 1.38% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 62,832.29 | 3,319.17 | 5.58% |
| NZX 50 Index | 13,258.28 | 113.09 | 0.86% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,875.60 | 30.20 | 0.34% |
| SSE Composite Index | 4,166.84 | 6.67 | 0.16% |